Glaxo Smith Kline results, Q3 2023
Net profit, assets, equity and cash flow for Q3 2023, against the same period a year earlier, from the published financial statements.
Net profit27.26 millionEGP · −44.3% vs the same period a year earlier
Total assets3.56 billionEGP · +13.1% vs the same period a year earlier
Shareholders' equity1.95 billionEGP · −11.3% vs the same period a year earlier
Operating cash flow194 millionEGP · +167.4% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Q3 2023 was about 27.26 million EGP, down −44.3% from 48.91 million EGP in Q3 2022.
- Total assets at the end of Q3 2023 were about 3.56 billion EGP, and shareholders' equity about 1.95 billion EGP.
- Operating cash flow for Q3 2023 was positive at 194 million EGP.
Key lines against the same period a year earlier
This periodQ3 2022Change
Net profit27.26 million48.91 million−44.3%
Gross profit179 million15.4 million+1062.3%
Total assets3.56 billion3.15 billion+13.1%
Total liabilities1.61 billion946 million+69.7%
Shareholders' equity1.95 billion2.2 billion−11.3%
Total liabilities and equity3.56 billion3.15 billion+13.1%
Operating cash flow194 million-288 million+167.4%
Investing cash flow84.04 million-3.59 million+2444.1%
Financing cash flow-61.12 million-73.96 million+17.4%
Net change in cash217 million-365 million+159.4%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy